Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130

MLA

Jary, Marine, et al. “Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130.” Molecular Oncology, vol. 16, Feb. 2022, pp. 2260–73. EBSCOhost, https://doi.org/10.1002/1878-0261.13173.

APA

Jary, M., Liu, W.-W., Yan, D., Bai, I., Muranyi, A., Colle, E., Brocheriou, I., Turpin, A., Radosevic-Robin, N., Bourgoin, P., Penault-Llorca, F., Cohen, R., Vernerey, D., André, T., Borg, C., Shanmugam, K., Svrcek, M., & Liu, W. (2022). Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130. Molecular Oncology, 16, 2260–2273. https://doi.org/10.1002/1878-0261.13173

Chicago

Jary, Marine, Wen-Wei Liu, Dongyao Yan, Isaac Bai, Andrea Muranyi, Elise Colle, Isabelle Brocheriou, et al. 2022. “Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130.” Molecular Oncology 16 (February): 2260–73. doi:10.1002/1878-0261.13173.